dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Estévez-Vázquez, Olga |
dc.contributor.author | Benedé-Ubieto, Raquel |
dc.contributor.author | Guo, Feifei |
dc.contributor.author | Gómez-Santos, Beatriz |
dc.contributor.author | Aspichueta, Patricia |
dc.contributor.author | Reissing, Johanna |
dc.contributor.author | Pericàs Pulido, Juan Manuel |
dc.contributor.author | Ciudin Mihai, Andreea |
dc.date.accessioned | 2022-03-11T12:00:39Z |
dc.date.available | 2022-03-11T12:00:39Z |
dc.date.issued | 2021-10 |
dc.identifier.citation | Estévez-Vázquez O, Benedé-Ubieto R, Guo F, Gómez-Santos B, Aspichueta P, Reissing J, et al. Fat: Quality, or Quantity? What Matters Most for the Progression of Metabolic Associated Fatty Liver Disease (MAFLD). Biomedicines. 2021 Oct;9(10):1289. |
dc.identifier.issn | 2227-9059 |
dc.identifier.uri | https://hdl.handle.net/11351/7139 |
dc.description | Fibrosis; Obesity; Palmitic acid (PA) |
dc.description.abstract | Objectives: Lately, many countries have restricted or even banned transfat, and palm oil has become a preferred replacement for food manufacturers. Whether palm oil is potentially an unhealthy food mainly due to its high content of saturated Palmitic Acid (PA) is a matter of debate. The aim of this study was to test whether qualitative aspects of diet such as levels of PA and the fat source are risk factors for Metabolic Syndrome (MS) and Metabolic Associated Fatty Liver Disease (MAFLD). Methods: C57BL/6 male mice were fed for 14 weeks with three types of Western diet (WD): 1. LP-WD—low concentration of PA (main fat source—corn and soybean oils); 2. HP-WD—high concentration of PA (main fat source—palm oil); 3. HP-Trans-WD—high concentration of PA (mainly transfat). Results: All types of WD caused weight gain, adipocyte enlargement, hepatomegaly, lipid metabolism alterations, and steatohepatitis. Feeding with HP diets led to more prominent obesity, hypercholesterolemia, stronger hepatic injury, and fibrosis. Only the feeding with HP-Trans-WD resulted in glucose intolerance and elevation of serum transaminases. Brief withdrawal of WDs reversed MS and signs of MAFLD. However, mild hepatic inflammation was still detectable in HP groups. Conclusions: HP and HP-Trans-WD play a crucial role in the genesis of MS and MAFLD. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Biomedicines;9(10) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Esteatosi hepàtica |
dc.subject | Àcids grassos saturats - Metabolisme |
dc.subject | Ratolins |
dc.subject.mesh | Non-alcoholic Fatty Liver Disease |
dc.subject.mesh | /metabolism |
dc.subject.mesh | Trans Fatty Acids |
dc.subject.mesh | /adverse effects |
dc.title | Fat: Quality, or Quantity? What Matters Most for the Progression of Metabolic Associated Fatty Liver Disease (MAFLD) |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/biomedicines9101289 |
dc.subject.decs | esteatosis hepática alcohólica |
dc.subject.decs | /metabolismo |
dc.subject.decs | ácidos grasos trans |
dc.subject.decs | /efectos adversos |
dc.relation.publishversion | https://doi.org/10.3390/biomedicines9101289 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Estévez-Vázquez O, Benedé-Ubieto R] Department of Physiology, Genetics and Microbiology, Faculty of Biology, Complutense University of Madrid, 28040 Madrid, Spain. Department of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University of Madrid, 28040 Madrid, Spain. [Guo F] Department of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University of Madrid, 28040 Madrid, Spain. [Gómez-Santos B] Department of Physiology, Faculty of Medicine and Nursing, University of Basque Country UPV/EHU, 48940 Leioa, Spain. [Aspichueta P] Department of Physiology, Faculty of Medicine and Nursing, University of Basque Country UPV/EHU, 48940 Leioa, Spain. Biocruces Health Research Institute, 48903 Barakaldo, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, 28220 Madrid, Spain. [Reissing J] Department of Internal Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany. [Ciudin A] Servei d’Endocrinologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Pericàs JM] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, 28220 Madrid, Spain. Unitat del Fetge, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain |
dc.identifier.pmid | 34680405 |
dc.identifier.wos | 000712389800001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |